Teva opens $110m sterile medicine plant in Hungary
pharmafile | October 16, 2012 | News story | Manufacturing and Production | Gödöllő, Hungary, Teva
Teva Pharmaceutical Industries has officially opened its new plant in Gödöllő, Hungary, for the production of sterile injectable pharmaceuticals.
The world’s largest generic drugmaker said the plant boosted Teva’s role in both Hungarian and international drug production, and is one of the biggest and advanced manufacturing sites in the world.
The Gödöllő facility has an annual production capacity of 160-200 million units of injectable drugs, made on six production lines that can operate in parallel, and will focus mainly on the production of cytotoxic drugs for cancer.
A 15,000 sq. m. production area and modular building structure makes the new plant “not only one of the biggest sterile pharmaceutical plants but also one of the most flexible ones in the world”, said Teva in a statement, noting that this will allow it to ramp up production of drugs to respond to patients’ needs.
It will be used to supply medicines to patients in more than 70 countries, mainly in the US, Europe and Far East, it added, noting that it will make cancer drugs have been in short supply in Europe.
In a speech at the inauguration of the plant, Teva chief executive Jeremy Levin highlighted the firm’s commitment to the highest quality drug production, and said the investment “will help us continue our work to provide important sterile medicines to people around the world”.
The chief executive of Teva Pharmaceutical Works Hungary, Mihály Kaszás, said: “We are very proud of the investment, but even more proud of our employees who dreamt of this plant, who planned it, built it, equipped it, and also who will work in it.”
Teva has been operating in Hungary since 1993 and employs more than 3,500 people in the country, with two other manufacturing facilities in Debrecen and Sajóbábony, making oral dosage forms and bulk active pharmaceutical ingredients (APIs), respectively.
Phil Taylor
Related Content
Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …
Sanofi and Teva partner for development of inflammatory bowel disease treatment
Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …
Teva’s cancer drug Bendeka protected from generics until 2031, judge rules
A US federal judge has ruled that generic versions of the cancer treatment Bendeka infringe …
